Clinical trials: Transthyretin Amyloidosis
Familial Amyloid Polyneuropathy, ATTR-PN
An Extension of Study Fx-005 Evaluating Long-Term Safety And Clinical Outcomes Of Fx-1006A In Patients With Transthyretin Amyloid Polyneuropathy
This study is designed to determine the long-term safety and tolerability of Fx-1006A as well as the effects of Fx-1006A on clinical outcomes in patients with ATTR-PN.
- Trial name
- NCT00791492
- Testing
- Fx-1006A
- Where
- 11 sites in Argentina, Brazil and 4 more
- Volunteers
- 86 people
- Sponsor
- Pfizer
Transthyretin (TTR)-Mediated Amyloidosis, Familial Amyloidotic Polyneuropathy (FAP)
The Study of an Investigational Drug, Revusiran (ALN-TTRSC), for the Treatment of Transthyretin (TTR)-Mediated Amyloidosis in Patients Whose Disease Has Continued to Worsen Following Liver Transplant
The purpose of this study was to evaluate the safety and effectiveness of revusiran (ALN-TTRSC) in adults with transthyretin-mediated amyloidosis (ATTR), whose disease has continued to worsen after liver transplantation.
- Conditions
- Transthyretin (TTR)-Mediated Amyloidosis, Familial Amyloidotic Polyneuropathy (FAP), ATTR Amyloidosis, Familial Amyloid Neuropathies
- Trial name
- NCT02595983
- Testing
- Revusiran
- Where
- 6 sites in France, Germany and 4 more
- Volunteers
- 12 people
- Sponsor
- Alnylam Pharmaceuticals
Amyloidosis Cardiac, Heart Failure
Screening, Characterization, and Longitudinal Follow-up of Patients With Cardiac Amyloidosis
Cardiac amyloidosis is a progressive disorder caused by extracellular deposition of amyloid fibrils in the heart, leading to heart failure and impaired cardiac function.
- Conditions
- Amyloidosis Cardiac, Heart Failure, Cardiac MRI, Spectroscopic Analysis
- Trial name
- NCT07577466
- Where
- Germany
- Volunteers
- 200 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Amyloidosis Transthyretin, Athlete Heart
Exercise Effect on Transthyretin Stability
The goal of this study to investigate if exercise predisposes to transthyretin instability. The investigators will evaluate the effect of exercise on transthyretin biochemistry.
- Trial name
- NCT04986826
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Oregon Health and Science University
Amyloidosis, Hereditary, Amyloidosis Cardiac
Subclinical Transthyretin Cardiac Amyloidosis in V122I TTR Carriers
Approximately 1.5 million of the 44 million Blacks in the United States are carriers of the valine-to-isoleucine substitution at position 122 (V122I) in the transthyretin (TTR) protein.
- Conditions
- Amyloidosis, Hereditary, Amyloidosis Cardiac, Amyloidosis, Familial, Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy
- Trial name
- NCT05489549
- Where
- 3 sites in United States
- Volunteers
- 500 people
- Sponsor
- University of Texas Southwestern Medical Center
Atrial Fibrillation (AF), Cardiac Amyloidosis
Early Detection of Concealed Cardiac Amyloidosis Using AI-ECG and CT-Derived Extracellular Volume in Patients With Atrial Fibrillation
This study investigates the clinical efficacy of a non-invasive screening protocol using AI-ECG and CT-ECV analysis for cardiac amyloidosis. The study targets on atrial fibrillation(AF) patients with "red-flag" indicators.
- Trial name
- SEARCH-AF (NCT07567508)
- Testing
- AI-ECG analysis, CT-ECV analysis, Atrial fibrillation treatment
- Where
- South Korea
- Volunteers
- 500 people
- Sponsor
- Samsung Medical Center
Amyloid Cardiomyopathy
Unmasking the Prevalence of AC in an Unselected Echocardiographic Population
This study will investigate the prevalence of echocardiographic red-flags of amyloid cardiomyopathy (AC) in patients undergoing clinically-indicated echocardiography (observational phase) and the prevalence of AC among…
- Trial name
- AC-TIVE (NCT04738266)
- Testing
- Amyloid Cardiomyopathy
- Where
- 16 sites in Italy
- Volunteers
- 381 people
- Sponsor
- University of Trieste
Transthyretin Amyloidosis
Evaluation of a Claims-based Algorithm for the Identification of Transthyretin-mediated Amyloidosis (ATTR) Amyloidosis in Medical Records
The primary objective of this study is to evaluate the diagnostic performance of an algorithm in identifying patients with ATTR amyloidosis.
- Trial name
- NCT04569903
- Testing
- Computer algorithm for ATTR
- Where
- United States
- Sponsor
- Yale University
Transthyretin Amyloid Cardiomyopathy
A Research Study to Look at the Distribution and Effects of Coramitug on Amyloid Deposits in Heart Tissue Using PET/CT Imaging in People With ATTR Amyloidosis.
The study is conducted in participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a heart disease that occurs in people with the disease ATTR amyloidosis.
- Trial name
- NCT07448623
- Testing
- Coramitug
- Where
- Netherlands
- Volunteers
- 14 people
- Sponsor
- Novo Nordisk A/S
Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction (HFPEF)
AI-based Echocardiography for Detection of Cardiac Amyloidosis
Cardiac amyloidosis is characterized by deposition of misfolded protein in the myocardium causing mainly heart failure symptoms with preserved left ventricular ejection fraction.
- Conditions
- Cardiac Amyloidosis, Heart Failure With Preserved Ejection Fraction (HFPEF), Left Ventricular Hypertrophy
- Trial name
- ORCHESTRA (NCT07529860)
- Testing
- AI-based echocardiogram
- Volunteers
- 200 people
- Sponsor
- Germans Trias i Pujol Hospital
Cardiomyopathy
Observational Epidemiological Study of Patients Suffering From Systemic Amyloidosis
observational epidemiological study of patients affected by systemic amyloidosis
- Trial name
- AMI-ER (NCT06866912)
- Where
- Italy
- Volunteers
- 750 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Cardiac Amyloidosis
Individualized Exercise Training in Cardiac Amyloidosis
Numerous clinical trials have demonstrated that transthyretin (TTR)-directed medical therapies can reduce the rate of functional decline in patients with transthyretin cardiac amyloidosis (ATTR-CM).
- Trial name
- GET-FIT ATTR (NCT07835867)
- Testing
- Exercise Intervention, Physical Activity Handout
- Volunteers
- 60 people
- Sponsor
- Oregon Health and Science University
Light-chain Cardiac Amyloidosis
Selinexor, Daratumumab, and Dexamethasone (XDd) for Light-Chain Cardiac Amyloidosis
The goal of this clinical trial is to evaluate whether selinexor combined with daratumumab and dexamethasone (XDd) can treat patients with advanced light-chain cardiac amyloidosis.
- Trial name
- NCT07743957
- Testing
- XDd
- Volunteers
- 63 people
- Sponsor
- Beijing Anzhen Hospital
Cardiac Amyloidosis
Diagnosis of Cardiac Amyloidosis With 99mTc-PYP; Comparison Between Planar Imaging, SPECT/CT and Cardiac-dedicated CZT Camera
1. Patients will undergo clinical and laboratory assessment, as well as imaging tests, at the discretion of the attending cardiologist and will be referred at their discretion to perform cardiac mapping using 99mTc-PYP. 2.
- Trial name
- NCT04146415
- Testing
- Spect scan with mTc99-PYP
- Volunteers
- 30 people
- Sponsor
- Tel-Aviv Sourasky Medical Center
Amyloid Cardiomyopathy, Transthyretin-Related
Single and Multiple Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of AG10
This is a single center, prospective, randomized, placebo-controlled study of AG10 in healthy adult subjects
- Trial name
- NCT03294707
- Testing
- AG10 oral tablet
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Eidos Therapeutics, a BridgeBio company
Amyloidosis; Systemic
A Study to Characterize the Biodistribution of 124I-Labeled AT-03 in Patients With Systemic Amyloidosis
This is a single center Phase 1 study is to evaluate the biodistribution of radiolabeled AT-03 in patients with systemic amyloidosis.
- Trial name
- AT03-001 (NCT05201911)
- Testing
- 124I-AT03
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Attralus, Inc.
Amyloid Transthyretin Cardiomyopathy
Study of Re-Treatment With ALXN2220 in Patients With ATTR-CM
This is a Phase 2, single-arm, multicenter study to evaluate the pharmacodynamics and safety of re-treatment with ALXN2220 in previous participants of Study NI006-101.
- Trial name
- NCT07213583
- Testing
- ALXN2220
- Where
- 6 sites in France, Germany and 2 more
- Volunteers
- 35 people
- Sponsor
- Neurimmune AG
Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Thailand ATTR-CM Registry
The investigators of this registry aim to study the natural history, clinical presentation, characteristics, and imaging findings of patients diagnosed with ATTR amyloidosis in Thailand longitudinally.
- Trial name
- NCT06338696
- Testing
- No intervention
- Where
- 8 sites in Thailand
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Hereditary Transthyretin-Mediated Amyloidosis With Polyneuropathy, hATTR-PN
TRITON-PN: A Study to Evaluate the Efficacy and Safety of Nucresiran in Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy
The purpose of this study is to: Determine the efficacy of nucresiran in patients with hATTR-PN by evaluating the effect on neurologic impairment, quality of life, nutritional status, disability, and gait speed Demonstrate…
- Trial name
- TRITON-PN (NCT07223203)
- Testing
- Nucresiran, Vutrisiran
- Where
- 61 sites in United States, Argentina and 20 more
- Volunteers
- 125 people
- Sponsor
- Alnylam Pharmaceuticals
Transthyretin Cardiac Amyloidosis
Exploratory Study Evaluating the Relevance of [68Ga]Ga-FAPI-46 for Staging and Identifying Progressing Patients With Transthyretin Cardiac Amyloidosis
Transthyretin cardiac amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by amyloid fibril deposition, leading to heart failure and arrhythmias.
- Trial name
- FAPICAM (NCT07549841)
- Testing
- [68Ga]Ga-FAPI-46
- Where
- France
- Volunteers
- 40 people
- Sponsor
- Nantes University Hospital